Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate the non-inferiority of Polymerase Chain
Reaction (PCR)-adjusted adequate clinical and parasitological response to artesunate plus
amodiaquine at Day 28 in two groups of patients treated at the beginning of an artesunate
plus amodiaquine implementation program and 24 months later.
The secondary objectives are Clinical and biological tolerability Evolution of gametocyte
carriage Proportion of patients without fever at Day 3 Proportion of patients without
parasite at Day 3 Treatment compliance Impact of implementation on anemia Measure of parasite
sensibility to amodiaquine